Login / Signup

Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?

Abdoulaye KarabouéPasquale F InnominatoNicholas I WreglesworthBoris DuchemannRené AdamFrancis A Lévi
Published in: British journal of cancer (2024)
Such emerging understanding of circadian rhythms regulation of antitumour immunity now calls for randomised clinical trials of ICIs timing to establish recommendations for personalised chrono-immunotherapies with current and forthcoming drugs.
Keyphrases
  • clinical trial
  • open label
  • double blind
  • phase ii
  • clinical practice
  • phase iii
  • placebo controlled